RT Journal Article
SR Electronic
T1 A Novel Gene Delivery System for Mammalian Cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 483
OP 488
VO 24
IS 2A
A1 GIBSON, BRIAN
A1 DUFFY, ANGELA M.
A1 FOGERITE, SUSAN GOULD
A1 KRAUSE-ELSMORE, SARA
A1 LU, RUYING
A1 SHANG, GAOFENG
A1 CHEN, ZI-WEI
A1 MANNINO, RAPHAEL J.
A1 BOUCHIER-HAYES, DAVID J.
A1 HARMEY, JUDITH H.
YR 2004
UL http://ar.iiarjournals.org/content/24/2A/483.abstract
AB Although gene therapy holds great promise for the treatment of both acquired and genetic diseases, its development has been limited by practical considerations. Nonviral efficacy of delivery remains quite poor. We are investigating the feasibility of a novel lipid-based delivery system, cochleates, to deliver transgenes to mammalian cells. Rhodamine-labelled empty cochleates were incubated with two cell-lines (4T1 adenocarcinoma and H36.12 macrophage hybridoma) and primary macrophages in vitro and in vivo. Cochleates containing green fluorescent protein(GFP) expression plasmid were incubated with 4T1 adenocarcinoma cells. Cellular uptake of labelled cochleates or transgene GFP expression were visualised with fluorescence microscopy. 4T1 and H36.12 lines showed 39% and 23.1% uptake of rhodamine-cochleates, respectively. Human monocyte-derived macrophages and mouse peritoneal macrophages had 48±5.38% and 51.46±15.6% uptake of rhodamine-cochleates in vitro. In vivo 25.69±0.127% of peritoneal macrophages were rhodaminepositive after intra-peritoneal injection of rhodamine-cochleates. 19.49±10.12% of 4T1 cells expressed GFP. Cochleates may therefore be an effective, non-toxic and non-immunogenic method to introduce transgenes in vitro and in vivo. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved